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A B S T R A C T
Now that a composite human genome has been sequenced (HGP), research has accelerated to discover precise genetic
bases of several chronic health issues, particularly in the realms of cancer and cardiovascular disease. It is anticipated
that in the future it will be possible and cost effective to regularly sequence individual genomes, and thereby produce a
DNA profile that potentially can be used to assess the health risks for each person with respect to certain genetically pre-
disposed conditions. Coupled with that enormous diagnostic power, it will then depend upon equally rapid research ef-
forts to develop personalized courses of treatment, including that of pharmaceutical therapy. Initial treatment attempts
have been made to match drug efficacy and safety to individuals of assigned or self-identified groups according to their
genetic ancestry or presumed race. A prime example is that of BiDil, which was the first drug approved by the US FDA
for the explicit treatment of heart patients of African American ancestry. This race-based approach to medicine has been
met with justifiable criticism, notably on ethical grounds that have long plagued historical applications and misuses of
human race classification, and also on questionable science. This paper will assess race-based medical research and
practice in light of a more thorough understanding of human genetic variability. Additional concerns will be expressed
with regard to the rapidly developing area of pharmacogenomics, promoted to be the future of personalized medicine.
Genomic epidemiology will be discussed with several examples of on-going research that hopefully will provide a solid
scientific grounding for personalized medicine to build upon.
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Introduction
Taking a broad perspective, Western Medicine gener-
ally has sought to deliver the very best and latest health
care cognizant of individual and group variability. For ex-
ample, in recent years clinical trials have been much
more attendant to better represent women in light of
possible differing health decisions and policies to that of
men. So too, race and/or ethnic group has been increas-
ingly addressed for some of the same reasons. Numerous
studies and reports have been devoted to the topic of
race-based medicine1–6.
However, biomedical research as well as clinical prac-
tice has endured an apparent uncomfortable and unset-
tled relationship involving human races. This is under-
standable given the ubiquitous lack of adequate defini-
tion and clarity for applying a workable concept of classi-
fication into racial categories. For the most part, medical
science has resorted to self-identification and self-report-
ing in its recruitment for clinical trials. Hence, recruits
assigned themselves to already existing categories. It is
probable that the general public in the USA has been ex-
posed formally to racial categorization though several
applications including the Federal Census Forms, law en-
forcement agencies, and health care studies and health
delivery services.
Indeed, considering the last of these, mainstream
news media continually broadcast the disparities in heal-
th care delivery that are based upon race/ethnic group
designations, such as White, African American, Hispanic,
Asian and others. These categories are found in the Fed-
eral Census forms and also are required to be used by
biomedical researchers receiving NIH funding1.
Since assignment to these racial categories is often by
individual or personal choice, it can be expected that de-
cisions are made according to a combination of biological
variables and sociocultural characteristics. Hence, the
conjoined label »race/ethnic group« seems entirely appro-
priate, at least in this instance. As a consequence, throu-
ghout much of the biomedical research literature, race
and ethnic group appear to have equal and nearly inter-
changeable status. A major question that has been raised
in that literature, and serves to focus this paper, is
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whether disparities in health care delivery and resultant
differences in treatment success are only due to socioeco-
nomic variables or are there possible underlying biologi-
cal/genetic influences that in part explain both variation
in susceptibility to certain diseases and the efficacy and
safety of administered pharmaceuticals or drugs?
Recently, the US Federal government has recognized
that this question should be addressed from a sound sci-
entific approach that attempts to sort out the relative
contributions of environment and heredity by establish-
ing the NIH Center to Study Genomics and Health Dis-
parities (NCSGHD). Whether this particular effort will
be successful is, of course, yet to be determined. How-
ever, considering the state of affairs with regard to cur-
rent pharmaceutical research based upon racial catego-
ries, there is good reason to be skeptical about any major
breakthroughs in dispelling health care disparities.
Race-Based Medicine
Pharmaceutical companies routinely have utilized ra-
cial categories in investigating drugs that can be tailored
toward selected populations, and thereby has been re-
ferred to as race-based therapeutics7 or race-based medi-
cine8. Their aim is to develop and market new medicines
to treat diseases that disproportionately affect certain
groups or races. Their concept of race presumably is
founded on self-identification or self-reporting but is pur-
ported to be indicative of the genetic variation and ances-
try of the self-defined group, for example, African Ameri-
cans. For this purpose, race is thus viewed as a proxy or
placeholder for yet to be determined genetic information
and specification. It might be mentioned that this com-
mercial interest in targeted drug development by phar-
maceutical companies is not restricted to race but to sev-
eral demographic divisions including gender and age
groups.
Hence, it is perhaps reasonable to surmise that drug
companies fundamentally are driven by a profit motive
along with their benevolent search for targeted medi-
cines, which, of course, is an acceptable business practice
under a capitalistic economy. However, there is an unsa-
vory instance of one drug that appears to have followed
this tailor-made development and marketing pathway
but unfortunately was subjected to very questionable
science7,9–10. This is the case of BiDil. BiDil is taken in pill
form that actually is composed of two generic drugs,
hydralazine and isosorbide dinitrate. Its primary physio-
logical function is vasodilatory (expands blood vessels)
and it has been shown to have clear therapeutic value in
the treatment of congestive heart failure. Therefore, it
was entirely legitimate to claim that BiDil was effica-
cious. However, it is the developmental pathway itself
that led to its approval as a targeted drug for African
Americans that raises troubling questions and hopefully
also raises some caution flags9.
A synopsis of the BiDil case can begin by noting that
about 20 years ago initial studies were done to investi-
gate the effectiveness of vasodilating drugs on congestive
heart failure. The two drugs used separately in the re-
search were hydralazine and isosorbide dinitrate. In one
trial, V-HeFT II, these two drugs were compared with an
ACE inhibitor that proved to be more effective, and this
placed the vasodilating drugs as just a backup treatment
for patients who didn’t do well on ACE inhibitors. Not to
be deterred, the principal investigator persisted research
efforts and was able to secure a patent in 1987 that de-
fined the method for using the two vasodilating drugs,
hydralazine and isosorbide dinitrate, that were then
combined in the 1990s into the single pill called BiDil. A
first attempt to receive FDA approval for BiDil was re-
jected because the initial drug trials did not meet FDA
standards9. This rejection occurred in 1997 or ten years
after patent approval and thus halfway through patent
rights protection period. It is surmised that the pharma-
ceutical company that supported the BiDil research and
held the patent rights backed out of the project at this
time because of the FDA rejection and shortened patent
life, both of which would have adversely impacted profit-
ability of BiDil9. Apparently, again not to be deterred, the
principal investigator went back to the original V-HeFT I
and »data mined« the results that showed vasodilating
drugs were especially effective in African Americans, at
least in the 49 patients in the trial. This positive finding
was sufficient for him to attain another patent in 2000,
which then extended protection from competition until
2020. Shortly thereafter, he engaged a second drug com-
pany to underwrite another clinical trial known as Afri-
can-American Heart Failure Trial (A-HeFT)7,9.
In the A-HeFT study involving a self-identified Afri-
can American sample of 1050 patients, BiDil was found
to reduce fatality by 43% and to decrease hospitalization
by 39%, when compared to the placebo group. In fact, the
A-HeFT trial was stopped early because of such positive
results. The next most significant step was when BiDil
received US FDA approval in June of 2005 and was de-
fined as race-specific, the first such drug ever to receive
that designation9.
Needless to say, this action generated controversy
along with some support from certain quarters. Issues
that surround commercial interests of drug companies
are certainly profound and warrant a continued vigilance
against what in the case of BiDil appears to place profit
in the forefront. For instance, in order to properly ad-
dress the criticism that BiDil might be just as effective in
non African Americans would require a full prospective
study that compares adequate samples of all so-called ra-
cial/ethnic groups. This would be a costly, time-consum-
ing endeavor that probably will not attract copious drug
company investment. Of course, »off label« use of BiDil
for a patient of any ancestral background can be done
with no additional testing. In the end, it is fully expected
that the development of drugs will continue to follow an
economic benefits model and a set of marketing strate-
gies that enhance the financial status of companies, but
hopefully will also adhere to reasonable profit motives,
and most importantly to sound scientific practices.
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Beyond troubling commercial maneuvers, there are
numerous additional faults within the BiDil case that es-
sentially rest upon compromises of scientific integrity. At
this point we can generalize to offer a critique of race-
-based medicine overall that may have explicit applica-
tion in BiDil but has been implicated throughout medical
research and practice both before 2005 and persists up to
the present time11.
Critique of Race-Based Medicine
Race as a social construct
There has been an ongoing and spirited discussion of
whether human races are biologically real or are entirely
social constructed4,12. In the latter view, based on the ide-
ology of postmodernism, race does not have objective re-
ality, or more succinctly this notion sometimes translates
as races do not exist. This statement certainly is support-
able if it refers to the outmoded typological thinking that
defined human races as mutually exclusive, genetically
homogenous (»pure«) categories. On the other hand, ac-
knowledging numerous constraints on any classificatory
use of race, does allow restricted definitions of biologi-
cal/genetic races to be made operational, albeit with du-
bious scientific value or practical application. Additio-
nally, the act of classifying races is possibly less problem-
atic than any attempts to satisfactorily assign all individ-
uals to those defined race categories.
However, even if the concept of biological race classifi-
cation is accepted formally within selected academic cir-
cles, this does not remove the major obstacles facing
race-based medicine. Furthermore, race labeling could
quite possibly do harm in the eyes of the public that often
wrongly equates races with invariant genetic determin-
ism. A corollary to this public opinion is that race-specific
labeling of medicines, directly infers that certain diseases
are therefore race-specific and inevitable, and this could
lend itself to possible stigmatizing and discrimination.
Insurance coverage is one area where a discrimination
concern appears to have legitimacy9.
Race category assignment
As already noted, assignment to race/ethnic groups in
medical research and practice is usually done through
personal choice and self-reporting. This means that cate-
gories may contain individuals who have little or possibly
even no direct ancestral connection to those categories.
Perhaps of some interest, the US Census Bureau has per-
mitted persons to identify themselves into more than one
race category, and in actuality this is the situation of a
large portion of the US population. With respect to
race-based medicine, because of a lack of clarity or con-
trol of the genetic makeup of and variation within cate-
gories, any pretext of race serving as an adequate proxy
for genetic ancestry is unfounded3,13.
Genetic basis of disease
Given the above limitation, it seems fair to conclude
that all medicines that are deemed race-specific do not
necessarily match up with underlying genetic causality
or even predisposition for the disease being treated or
the drug dose being regulated. Later in this paper the
field of pharmacogenomics will be discussed, which does
attempt to associate precise nucleotide sequences with
specific diseases. However, race-based medicine by itself
does not do this. More particularly, BiDil is not a pharma-
cogenomic drug, it is not targeted to a detectable genetic
variant.
Genetic variation within and differences between
so-called racial groups
A fundamental flaw of race-based medicine is a failure
to fully appreciate that a large degree of genetic variation
that exists within self-reported racial groupings, in part
due to the historical mixing among US populations, but
more importantly as an expected condition of any reason-
ably large demes or gene pools. This flaw parallels histor-
ically earlier misguided attempts to classify biological
races as homogeneous (»pure«) and distinct. As a conse-
quence of genetic variation among individuals, prescrib-
ing a race-specific drug might increase the probability of
efficacy but by an unknown degree. There is a final mat-
ter to consider with regard to the lack of knowledge of
variability at the genetic level, and this has to do with
gene expression related to gene ´ gene and gene ´ enviro-
nment interactions13. This is more appropriately taken
up when we consider the next topic of pharmacogenomics.
In summing up this section, it must be said that the
controversy stemming from the marketing of BiDil as a
race-specific drug might well be resolved through con-
certed research to determine what if any gene variants
are associated directly with individual, not racial group,
responses to the use of this treatment in congestive heart
failure. That, in essence, is the direction pharmacogeno-
mics claims to be moving toward.
Pharmacogenomics
A major aim of pharmacogenomics is to ascertain a
genotype association with pharmacology in order to pro-
vide a more personalized drug treatment. As would be
expected much of the research in this field is carried out
within or with the support of pharmaceutical compa-
nies14. However, it can be pointed out that one of the US
Federal NIH agencies, the National Institute of General
Medical Sciences, hosts the Pharmacogenetics Research
Network (PGRN) that states a vision – To lead discovery
and advance translation in genomics in order to enable
safer and more effective drug therapies15. Its mission is
to promote innovative research in pharmacogenetics and
also serve as a clearing house for disseminating knowl-
edge about the impact human genetic variation has upon
drug responses, for example, results of genotype associa-
tions noted above.
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The usual research method for determining genotype
associations is through sequencing of Single Nucleotide
Polymorphisms or SNPs. One such study is that of Ra-
faiel, et al.16 in which they were able to show, among
other findings, that efficacy and safety of different cancer
treatments varied across race/ethnic groups according to
SNP polymorphisms. SNP sequencing methodology also,
of course, applies to initially establishing an association
or marker between a particular condition or disease en-
tity and a specified gene variant or locus, which when
discovered subsequently can be tested against various
drug treatments, as was done in the aforementioned can-
cer study16.
Multiple laboratory strategies have been employed
ranging from whole genome DNA sequencing for SNPs
down to RNA transcriptomes, the later method being
more efficient and less costly. To expedite this approach,
the National Human Genome Research Institute (NHGRI)
has undertaken an effort to generate a haplotype map
(HapMap) of the human genome that will consist of com-
monly occurring SNPs that define a rather smaller num-
ber of ancestral haplotypes. Whole genome sequencing
does generate a very large amount of genetic variability
results that only roughly correlates with designated race/
ethnic groups.
On the other hand, once particular SNP allele associa-
tions have been ascertained they may be subjected to
race/ethnic group distribution comparisons, as in some of
the earliest reported associations for hemochromotosis,
sickle cell anemia and cystic fibrosis. However, these
broad group associations could hardly be considered very
direct and so far have not led to successful development
of personalized drug treatments for any of them.
One of the more intriguing associations has been
found with respect to an ethnic/race group distribution of
the ApoE4 gene variant that is a risk factor for Alzhei-
mer disease. The ApoE4 variant ranges in frequency of
9% in Japanese to 19% in African Americans, yet the ac-
tual risk for expressing Alzheimer disease is reversed to
show a relatively lower six times increase for African
Americans, while in Japanese the risk markedly increa-
sed to 35 times17. Genetic or environmental modifiers of
the gene were implicated in this finding. Clearly, possess-
ing the SNP variant associated with a particular condi-
tion does not necessarily predict the outcome. Rather,
SNPs might better be viewed as evidence of a genetic pre-
disposition that may or may not be realized depending
upon a number of factors, most importantly gene x gene
and gene x environment interactions13, and also of signif-
icance to note here is an ever-increasing research inter-
est in how epigenetics affects gene expression.
A further consideration is that knowledge of a partic-
ular genetic risk profile, such as presence of the ApoE4
marker, may be unsettling for some, especially those in
their early adult years, due to the current inability to of-
fer much in the way of treatment for Alzheimer disease.
Another caution flag was raised in a report by Rotimi
and Jorde (2010)11 that showed ethnic group variation
with an HLA SNP and hypersensitivity to the drug
Abacavir. Abacavir is administered in the treatment of
HIV and AIDS. Negative reaction to this drug, in the
form heart attacks, is found in European Americans at
an average rate of nearly 6%. In two African populations
the hypersensitivity SNP allele did not appear at all in
the Yoruba from Nigeria, but showed an average fre-
quency of 13.6% in the Masai of Kenya. In this case,
race/ethnic group labels such as African or Black would
not be at all meaningful with regard to informed genomic
understanding or in medical practice. It is important to
note, however, that the US FDA recommended that all
groups be screened for the HLA hypersensitivity allele ir-
respective of their ethnic affiliation or ancestry11.
Genomic Epidemiology
These kinds of problems in genomic medicine are pro-
spectively resolvable as continued research efforts are
made especially in the area of genomic epidemiology. Ma-
jor initiatives along this direction are being taken by the
NIH funded National Human Genome Research Insti-
tute (NHGRI) and the Genome-Wide Association Study
(GWAS) both of which are scanning the entire genome in
search of SNP markers that are significantly associated
with diseases and conditions in individuals. Positive re-
sults or »associations« thus far have been found for Type
2 diabetes, Parkinson’s disease, heart disorders, obesity
and prostate cancer18.
As an update regarding Alzheimer disease, new re-
search has gone beyond the ApoE4 marker to recently
discovering several additional SNPs through genome-
-wide association studies showing putative risk genetic
variants or candidate genes19. Hopefully, this work will
lead to better diagnosis and possibly even eventual pre-
ventative treatment measures for Alzheimer disease20.
As already noted, genotype associations do not neces-
sarily identify the causal gene, a search that may be facil-
itated by conducting exome screening rather than the
whole genome. This approach could lead to highly infor-
mative candidate gene markers, or »driver mutations« in
the parlance of oncogenetics21. Another of these large
projects within NHGRI is that of the 1000 Genomes Pro-
ject, which to date actually has sequenced over 2000
genomes, and has been making their data readily avail-
able online, along with a tutorial for how to access and
use the data sets22.
Still another project under NHGRI sponsorship is un-
derway at Howard University, in Washington, DC23. A
main component of this research deals with Africans and
African population descendents who were involuntarily
dispersed to other world areas including the Caribbean
and USA. The focus of this project is on genetic epidemi-
ology in a multigenerational search for associations with
diabetes, hypertension and obesity, all conditions that
have adversely impacted the health of peoples of African
descent. Additional projects at Howard University are di-
rected toward a genetics ´ environment study of asthma
in African Americans and also a genetic epidemiology
study of breast cancer in African American women23.
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A final project to mention here is housed at the
MalariaGEN Resource Centre, University of Oxford, UK24.
Four initiatives have been defined, including; a) genome-
-wide association with severe malaria, b) genetic deter-
minants of immune response, c) genetic diversity in ma-
laria endemic regions, and d) genetic linkage studies of
resistance to malaria. All of these hopefully will shed
some light on the vexing issue of genetic variation that is
found among individuals who are assigned or assign
themselves to presently defined racial categories. This
MalariaGEN project, as well as others noted above, are
also addressing ethical considerations with respect to ge-
nome research, particularly the vexing problem of in-
formed consent.
Looking Ahead
For the foreseeable future it would appear that race-
-based medicine will continue to find an awkward and at
times, contestable, place in medical research and in clini-
cal practice. An optimistic viewpoint is that race catego-
ries can prove meaningful in health care and research
with careful training of medical personnel25,26. However,
as a contrary move, an advisory has been made by oppo-
nents of race-based medicine to abstain from participa-
tion in racial category studies and to refrain from the use
of available race-specific drugs27. Perhaps this move will
encourage an even more rapid transfer of genetic iden-
tity from that of a dubious race label to individual geno-
mes. Along that direction, Crews and Gerber (2008) sug-
gested that race categories used in medicine be replaced
by already well-studied Ancestry Informative Markers
(AIMs) but referenced to an individual level and thereby
referred to as IGA (individual geographic ancestry)3. In a
related line of inquiry, commercial enterprises are offer-
ing individual DNA testing of percentages of ancestry for
ancestral populations, such as BioGeographical Ancestry
(BGA)28. It is not yet evident whether these DNA lineage
approaches have been incorporated directly into medical
research or practice.
Regarding the cost involved of screening, it would ap-
pear that genomic medicine will be taking full advantage
of rapidly advancing and cheaper methods for DNA and
RNA sequencing and testing (including high throughput
and nanotechnology), and will become increasingly de-
pendent on these methods for diagnosing and protecting
patients in terms of drug appropriateness and dosage
level. Pharmacogenomics as a mainstay of personalized
medicine heralds in a potentially safer and more effective
delivery of health care to the individual.
However, it is very important to appreciate that nei-
ther race-based nor genomic medicine will replace the
time-honored and highly successful other diagnostic and
therapeutic insights available to the clinician, derived
from such factors as gender, age, lifestyle and family his-
tory. From a clinical perspective, these constitute risk
factors. To single out one of these, family history has in
fact been found in a comparative framework to be more
informative than personal genomic screening in a sub-
study of the Framingham Genetic Research Study dealing
with atrial fibrillation29, as well as in a risk assessment
for breast, colon and prostate cancer30, both study results
reported late this past year.
Recommendations
The major problems discussed in this review regard-
ing the diagnosis and treatment plans for conditions of a
genetic nature might be effectively addressed through
concerted educational efforts and professional develop-
ment. There are several partially overlapping and inte-
grated avenues to this approach, such as more intensive
training of physicians in genomic medicine, expanded in-
clusion of genetic counselors in patient interactions be-
tween physicians and patients, an introduction of patient
advocates who are able to assist persons in making deci-
sions more directly than is customarily expected of or
ethically permitted by genetic counselors, and to locate
support groups and online resources that can provide
useful information and guidance.
The complexity and crush of ever-expanding amounts
of genetic information may well be overwhelming to
most persons seeking medical assistance, and probably
even to a high proportion of health professionals as well.
Yet intensifying genomic training into a medical school
curriculum would impose a substantial burden and is not
likely to occur. Thus, the role of genetic counselors should
be much more routinely integrated into the care of pa-
tients and parents of patients dealing with genetically in-
fluenced conditions. Patient advocates fill a somewhat
different niche to that of the genetic counselor. Tradi-
tionally, and for good reason, ethical standards expected
genetic counselors to remain nondirective in their role of
providing complete, accurate, and up-to-date genetic in-
formation to clients31. In more recent years the non-
directive stance has been challenged by a psychosocial
approach32 that seems to establish a more active and in-
teractive relationship between the counselor and client.
Here is where a patient advocate, who would be fully pre-
pared to process and impart the complexities of genetic
information with clients, would assist by offering profes-
sional advice, but clearly without coercion or imposing
their own values, and in consort with a physician’s guid-
ance. Other health professionals, including nurses and
physician associates also might be anticipated to carry
some of the load imposed by genomic medicine applica-
tions. Finally, presuming that shared experiences do of-
fer empathetic consolation, prospective clients of ge-
nomic medicine might well benefit from interacting with
online support groups. Furthermore, taking full advan-
tage of current technological developments, web-based
resources could provide very personal guidance through
the labyrinth of genetic diagnoses and prognoses that
may or may not have any or even adequate courses of
treatment.
These recommendations essentially deal with educat-
ing both professionals and public regarding the promise
and practice of genomic medicine. Just as importantly, it
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is necessary to reign in the overstating of immediate ben-
efits derived from personal genomics. A viewpoint ex-
pressed recently by a physician and geneticist33 is that
expanding genetic knowledge in time will be very signifi-
cant in terms of understanding the hereditary nature of
some diseases, and thereby enhance diagnostic power,
while providing potentially valuable information to per-
sons who might be at high risk for developing certain dis-
eases themselves, or for prospective parents to guide in
their family planning decisions. He added, however, that
at the present time personal genetic information can
play only a small role in the overall picture for assessing
individual health33. Unfortunately this suggests that race-
-based medicine will persist in some fashion into the fu-
ture prior to a transition to a more realized practice of
genomic-based personalized medicine.
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KRITIKA RASNO-BAZIRANE I GENOMSKE MEDICINE
S A @ E T A K
Nakon sekvenciranja kompletnog ljudskog genoma, znanstvenici su stavili naglasak na otkrivanje geneti~ke baze
nekoliko kroni~nih zdravstvenih pitanja, ve}inom s podru~ja tumora i kardiovaskularnih oboljenja. Anticipirano je ka-
ko }e u budu}nosti biti mogu}e i nov~ano prihvatljivije redovito sekvencirati individualni genom, te shodno tome ispro-
ducirati DNA profil koji se potencijalno mo`e koristiti za otkrivanje zdravstvenih rizika svakog pojedinca u odnosu na
njegovu potencijalnu geneti~ku predispoziciju. Pra}eno s tom sna`nom dijagnostikom, jednako }e ovisiti i o jednako
ulo`enim naporima razvoja personaliziranih tretmana lije~enja, uklju~uju}i i farmaceutsku terapiju. Po~etni poku{aji
tretmana bili su usmjereni ka povezivanju u~inkovitosti i sigurnosti lijeka za pojedince odre|ene skupine na osnovi
njihovog geneti~kog naslije|a ili pretpostavljene rase. Glavni primjer je lijek pod nazivom BiDil, prvi koji je odobren od
US FDA za izri~itu upotrebu sr~anih bolesnika Afri~koameri~kog porijekla. Ovo rasno bazirano lije~enje s pravom je
podleglo kritici, posebno na eti~koj razini koje je dugo vremena bilo poput kuge, te se koristilo za neopravdane klasifika-
cije unutar ljudske vrste. Ovaj rad `eli odrediti rasno bazirana medicinska istra`ivanja i praksu u svjetlu cjelokupnog
razumijevanja ljudske geneti~ke varijabilnosti. Dodatna zabrinutost iskazana je u odnosu na brzo rastu}e podru~je
farmakogenomike – budu}nosti personaliziranih lijekova. Genetska epidemiologija biti }e diskutirana kroz nekoliko
primjera teku}ih istra`ivanja. Ovaj rad }e procijeniti rasno bazirana medicinska istra`ivanja i praksu u svjetlu podrob-
nijeg razumijevanja ljudske genetske varijabilnosti.Dodatna pa`nja posve}ena je ubrzanom razvoju podru~ju farmako-
genomike, koja se smatra budu}no{}u personalizirane medicine. Genomska epidemiologija diskutirana je kroz nekoliko
primjera kontinuiranog istra`ivanja koje }e pru`iti solidne znanstvene temelje za izgradnju personalizirane medicine.
